Exhibitors Search
Gwangju Institute of Science and Technology
| Exhibition | KOREA LAB Autumn |
|---|---|
| Booth no. | A19 |
| Country | Korea, South |
| Address | 123, Cheomdangwagi-ro, Buk-gu, Gwangju, Korea |
| Tel (Rep.) | 062-715-3477 |
| Website | http://www.gist.ac.kr |
Company Introduction
We are searching for out-licensing opportunities for following technologies:
1) Next-generation Cancer Immunotherapy Based on Direct Control of TCR Avidity , 2) A Novel Therapeutic Compound for Overactive Bladder(OAB) 3)A Novel Therapeutic Compound for skeletal muscle wasting(sarcopenia), 4)Antimicrobial peptoids for treatment of multidrug resistant Gram-negative bacteria, 5)Highly sensitive colorimetric immunoassay sensor for virus detection
1) Next-generation Cancer Immunotherapy Based on Direct Control of TCR Avidity , 2) A Novel Therapeutic Compound for Overactive Bladder(OAB) 3)A Novel Therapeutic Compound for skeletal muscle wasting(sarcopenia), 4)Antimicrobial peptoids for treatment of multidrug resistant Gram-negative bacteria, 5)Highly sensitive colorimetric immunoassay sensor for virus detection
Promotional video
Exhibit Item
1) Next-generation Cancer Immunotherapy Based on Direct Control of TCR Avidity , 2) A Novel Therapeutic Compound for Overactive Bladder(OAB) 3)A Novel Therapeutic Compound for skeletal muscle wasting(sarcopenia), 4)Antimicrobial peptoids for treatment of multidrug resistant Gram-negative bacteria, 5)Highly sensitive colorimetric immunoassay sensor for virus detection
Exhibit Item Images
-
Product Name : Next-generation Cancer Immunotherapy Based on Direct Control of TCR AvidityRetroviral transduction of TM domain of IGSF4 can increase TCR avidity, which may be critical in developing effective adoptive T-cell immunotherapy for cancer. -
Product Name : Composition for treating skeletal muscle wasting(sarcopenia)Our compound has been already approved by FDA and it is widely studied under clinical trials with diverse diseases. Not only does this compound make the myotubes larger, but it improves muscle function in mouse muscle atrophy models. -
Product Name : A Novel Therapeutic Compound for Overactive Bladder (OAB)A number of novel chemical compounds activating BKCa channel were selected and their efficacy on controlling OAB behaviors were tested in vitro and in vivo model system. -
Product Name : Antimicrobial peptoids for treatment of multidrug resistant Gram-negative bacteriaWe are developing novel class antibiotics based on one of peptidomimetics, peptoids, to overcome drawbacks of antimicrobial peptides. Peptoids had higher in vivo stability than peptides from previous biodistribution study. Based on membrane disruption mechanism, antimicrobial peptoids showed antimicrobial activity against broad spectrum pathogens. -
Product Name : Highly sensitive colorimetric immunoassay sensor for COVID-19 virus detectionOur innovative colorimetric sensing technology allows the detection of the COVID-19 virus on the sensor surface by a distinct color change. Compared with conventional COVID-19 detection method, our technology shows high sensitivity and fast detection time without gene amplification, and can also detect airborne viruses.'
Exhibit Description
We are searching for out-licensing opportunities for following technologies:
1) Next-generation Cancer Immunotherapy 2) Drug candidate for Overactive Bladder 3) Drug candidate for skeletal muscle wasting(sarcopenia), 4)Antimicrobial peptoids(peptide mimetic) 5)Highly sensitive colorimetric immunoassay sensor for virus detection
1) Next-generation Cancer Immunotherapy 2) Drug candidate for Overactive Bladder 3) Drug candidate for skeletal muscle wasting(sarcopenia), 4)Antimicrobial peptoids(peptide mimetic) 5)Highly sensitive colorimetric immunoassay sensor for virus detection
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.